Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity

As biologics, biosimilars and GLP-1s drive demand for sterile drug products, CMOs and CDMOs are investing in fill-finish, lyophilization, inspection and packaging capacity to keep pace with a dynamic injectable market.